Latest filings (excl ownership)
8-K
Oragenics, Inc. Announces Notification of Noncompliance with Additional NYSE American Continued Listing Standards
19 Apr 24
8-K
Shareholder Nominations Pursuant to Exchange Act Rule 14a-11
15 Apr 24
10-K
2023 FY
Annual report
29 Mar 24
8-K
Oragenics Appoints James Kelly MD, Chief Medical Officer to Lead Phase II Clinical Trials for Treating Concussion
18 Mar 24
8-K
Oragenics Announces Closing of Public Offering
1 Mar 24
424B5
Prospectus supplement for primary offering
29 Feb 24
8-K
Oragenics Announces Pricing of Public Offering
28 Feb 24
8-K
Oragenics Announces Proposed Public Offering
27 Feb 24
FWP
Free writing prospectus
27 Feb 24
424B5
Prospectus supplement for primary offering
27 Feb 24
8-K
Oragenics, Inc. Announces Leadership Transition
12 Feb 24
8-K
Oragenics, Inc. Announces Expiration of Its Investment Banking Engagement Agreement
7 Feb 24
8-K
Other Events
5 Feb 24
8-K
Oragenics Announces Termination of At-The-Market Offering Program
23 Jan 24
8-K
Other Events
16 Jan 24
FWP
Free writing prospectus
16 Jan 24
424B5
Prospectus supplement for primary offering
16 Jan 24
S-8
Registration of securities for employees
10 Jan 24
8-K
Oragenics Completes Acquisition of Odyssey Health’s Neurological Assets
2 Jan 24
8-K
Completion of Acquisition or Disposition of Assets
29 Dec 23
8-K
Material Modifications to Rights of Security Holders
15 Dec 23
8-K
Amendments to Articles of Incorporation or Bylaws
8 Dec 23
8-K
Regulation FD Disclosure
20 Nov 23
DEFA14A
Additional proxy soliciting materials
16 Nov 23
10-Q
2023 Q3
Quarterly report
9 Nov 23
8-K
Oragenics Issues Update to Shareholders
2 Nov 23
DEFA14A
Additional proxy soliciting materials
2 Nov 23
DEFA14A
Additional proxy soliciting materials
30 Oct 23
DEF 14A
Definitive proxy
30 Oct 23
PRE 14A
Preliminary proxy
6 Oct 23
8-K
Departure of Directors or Certain Officers
5 Oct 23
8-K
Oragenics to Acquire Odyssey Health’s Neurological Drug Technology Pipeline Including Concussion Drug Candidate
5 Oct 23
8-K
Oragenics Enters into Agreement with Lantern Bioworks for Replacement-Therapy Assets
29 Sep 23
8-K
Termination of a Material Definitive Agreement
15 Sep 23
8-K
Changes in Registrant's Certifying Accountant
18 Aug 23
10-Q
2023 Q2
Quarterly report
11 Aug 23
8-K
Departure of Directors or Certain Officers
10 Aug 23
D
$850.00 k in equity, sold $850.00 k, 2 investors
7 Aug 23
8-K
Oragenics, Inc. Announces Private Placement
7 Aug 23
8-K
Oragenics Project to Develop a Variant-Agnostic Protein Antigen for Use in its COVID-19 Intranasal Vaccine Receives Funding from CQDM
5 Jun 23
Latest ownership filings
SC 13G
Lind Global Fund II LP
6 Mar 24
SC 13D
Odyssey Health, Inc.
12 Feb 24
5
ROBERT C KOSKI
22 Jan 24
4
J MICHAEL REDMOND
2 Jan 24
3
J MICHAEL REDMOND
2 Jan 24
4
Fred Telling
1 Dec 23
144
Notice of proposed sale of securities
30 Nov 23
4
JOHN P GANDOLFO
6 Oct 23
4
Bruce A. Sr. Cassidy
6 Oct 23
3
JOHN P GANDOLFO
6 Oct 23
3
Bruce A. Sr. Cassidy
6 Oct 23
4
ROBERT C KOSKI
10 Aug 23
4
CHARLES L POPE
10 Aug 23
4
Kimberly M Murphy
10 Aug 23
4
ALAN W DUNTON
10 Aug 23
4
Janet Huffman
10 Aug 23
4
Fred Telling
10 Aug 23
4
Janet Huffman
8 Mar 23
3
Janet Huffman
8 Mar 23
4
ROBERT C KOSKI
3 Jan 23
4
ROBERT C KOSKI
16 Dec 22
4
ROBERT C KOSKI
15 Dec 22
4
ROBERT C KOSKI
12 Dec 22
4
ROBERT C KOSKI
9 Dec 22
4
ROBERT C KOSKI
1 Dec 22
4
ROBERT C KOSKI
2 Aug 22
4
CHARLES L POPE
2 Aug 22
4
Michael O'Keefe Sullivan
2 Aug 22
4
Fred Telling
2 Aug 22
4
ALAN W DUNTON
2 Aug 22
4/A
Fred Telling
27 Jun 22
4
Kimberly M Murphy
24 Jun 22
4
Michael O'Keefe Sullivan
24 Jun 22
4
Fred Telling
24 Jun 22
4
Fred Telling
21 Jun 22
4
Fred Telling
25 May 22
4
Fred Telling
23 May 22
4
Fred Telling
20 May 22
4
Fred Telling
1 Apr 22
4
Michael O'Keefe Sullivan
30 Mar 22